I spoke to people at Exelixis. They told me they had talked to that guy after his report. He doesn't understand; is what I was told. Also they told me to be patient and June 1st etc. we will hear the true results, to date, for Metero and the Roche trials. Orals will be right up to the moment and add info. the Abstracts don't contain. So there you have it. If you want facts or question some reports or post by outsiders go to the source; Exel.
Geneva, Switzerland, 17 April 2015 -- A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to treat melanoma, the authors of a new academic clinical trial in Europe have reported at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland.
Dr. Oliver Gautschi, a medical oncologist from Lucern Cantonal Hospital in Switzerland, presented the results of the retrospective EURAF cohort study, which included lung cancer patients whose tumours carried specific mutations in the BRAF gene. The study was conducted by a network of European oncologists, without company involvement.
BRAF mutations are commonly seen in melanoma patients, and are found in about 2% of lung adenocarcinomas, Gautschi explains. Several inhibitors of the B-Raf protein, including vemurafenib and dabrafenib, have been developed for use in melanoma patients, however there is currently no approved drug for BRAF-mutant lung cancer.
As a result, experience with B-Raf inhibitors in lung cancer remains limited. "In the current study, we wanted to find out how many patients in Europe received B-Raf inhibitors outside of a clinical trial, and what their outcomes were," Gautschi says.
The EURAF study gathered information on 35 lung cancer patients who had been identified as carrying BRAF mutations, who were treated with B-Raf inhibitors between 2012 and 2014.
Most of those patients received vemurafenib, some dabrafenib, and one sorafenib. Overall response rate was 53% as measured by the widely used Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. Overall, progression-free survival time in this group was 5 months.
Most patients were pretreated, and not eligible for enrolment in a clinical trial, which means these results are encouraging, the researchers say, although the study's small size and retrospective nature mean the analysis of the magnitude of benefit should be treated cautiously.
"The bottom line is that clinicians should be sure to test patients for so-called 'rare' driver mutations in lung cancer, because individual patients may derive substantial benefit from targeted therapy," says Gautschi.
Commenting on the findings, Dr David Planchard, pulmonary oncologist at Gustave Roussy in Villejuif, France, said that the results of the trial confirm the benefit of B-Raf inhibitors in BRAF-mutant non-small cell lung cancer. The current trial also confirmed the good tolerance of the drugs with no new side-effects, he said. Planchard and colleagues have presented a separate phase II study in this area with dabrafenib .
"This trial is important because due to the low frequency of this mutation in non-small cell lung cancer we will have few trials on this population," Planchard commented. "The more data we have, the better we understand how important it is to test for the mutation, especially in adenocarcinomas, and to expose mutation-positive patients to a specific B-Raf inhibitor."
The results also add to growing support for the approval of B-Raf inhibitors for use in lung cancer, Planchard added. This is important because the rarity of this mutation means that performing the kind of randomized phase III trials usually required for licensing approval will be extremely difficult, he noted.
Looking ahead, it will also be important to see results of combination therapy with inhibitors of B-Raf and a related protein, Mek, in non-small cell lung cancer carrying BRAF-V600E mutations, the researchers note, as this combination has shown a higher clinical benefit in BRAF-mutant melanoma.
Wrong! Wrong! Wrong! I have talked to people other than IR. I did work there for 10yrs.. I won't get info. others can't get. But the first 2 sentences are exactly what I was told. The other thing is I was told too be patient and we will hear more June 1st.
I made a mistake I wasn't told Metero. My mind slipped again. Sorry. I was told Cabo and Cobi info. would be given. June 1st was said to be the day to take note of what is made available.
From Street article: With the designation, cabozantinib is now also eligible for a Priority Review of a New Drug Application.Nothing but good news today.That's why the price rose today.There is no getting around that fact.
Back in 2008 or 2009, I believe you used the handle nomad_celcius12. You posted incessantly venomous comment after comment. Nothing but your personal opinions without merit .You just wasted your time.Then you stopped after about 5 years.Now your back as nomad_1957;posting the same kind of worthless nonsense.
He may have an agenda. Or he may not. 1 of lifes mysteries, if you ask me, trying to understand someone else. There sure are lots of worthless post here. That I'm sure of. Why would someone try to sell people on some stocks or a Website perporting to help people make a fortune on stocks is beyound me. Then people with posts that do nothing but say it's going green today or it will be at $5 by close. Such a waste of time, worhtless junk. Oh well there is no accounting for stupidity. Of course sometimes I also make mistakes; I'm not perfect.
I like this part:"Once a drug receives Fast Track designation, early and frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and review process. The frequency of communication assures that questions and issues are resolved quickly, often leading to earlier drug approval and access by patients."
Go to the ASCO homepage and work your way around the site. It may answer many questions you have. It's easy. Good luck.
AVEO has similar manipulation I guess. Day's Range: 1.81 - 3.50, Prev Close: 1.60, Close 2.23 Up 0.63(39.38%) 4:00PM EDT. Or is it just profit taking; like IR told me is what is happening with Exel. Profit taking of pennies not dollars? I didn't like that answer.
What an genius. It sure doesn't look like it's moving to $8 or even $4; like another said it would. Now tell me what the outcome of the NBA final will be. And by how many points the games will be won by. It's ridiculous and point less telling the world what you think the price will be.
Seattle Genetics has been around since about 1997. They have been trying to find drugs to combat cancer using monoclonal antibody therapy, a form of immunotherapy, and have one approved drug; ADCETRIS. So you see it is not so easy or even clear that the hype will prove to reap many quick, or any great number of successes.
If not over a Holiday weekend.Monday would be outstanding. It should be soon. I'll be trickled pink if it happens to be great news and maybe beats all guesses. I've waited long enough after a $12 or higher price to the price slide that took us where we are today. Cheers!